Cardiovascular Disease Pharmacogenomics

  • Bishwanath Chatterjee


Cardiovascular disease (CVD), commonly known as heart disease, is the leading cause of death all over the world. Nearly one in four deaths worldwide is attributed to CVD. Generally, CVD constitutes a number of overlapping structural and functional irregularities in the heart and blood vessels, which together constitute the cardiovascular system. Given this, the corresponding drugs also either can treat or prevent these overlapping conditions. Often, more than one drug is prescribed to treat a medical condition, since one medication alone cannot remedy the problem. High mortality and morbidity due to CVD automatically requires physicians to treat CVD aggressively, leading to adverse drug reactions. Still, some patients do not respond positively even if the strongest recommended drug dosage is administered. Research in the CVD field has demonstrated linkage between gene variation and the severity of diseases such as blood cholesterol level or blood pressure. Correspondingly, research over more than three decades has established the linkage of genetic variation with the efficacy of CVD treatment in the cohorts of different CVD disease types. In this chapter, recent advances in the field of cardiovascular pharmacogenetics and pharmacogenomics are summarized.


Statin Therapy Cardiovascular Drug SLCO1B1 Gene GNB3 C825T Polymorphism Pharmacogenomic Application 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Armitage J (2007) The safety of statin in clinical practice. Lancet 370:1781–1790PubMedGoogle Scholar
  2. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH (2005) Pharmacogenetic association of the angiotensin converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (Gen-HAT) study. Circulation 111:3374–3383PubMedGoogle Scholar
  3. Arnett DK, Claas SA, Glasser SP (2006) Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 44:107–118PubMedGoogle Scholar
  4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G et al (2005) Cholesterol Treatment Trialists’ (CTT) collaborators. Lancet 366:1267–1278PubMedGoogle Scholar
  5. Ballantyne CM (2003) Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 92:3K–9KPubMedGoogle Scholar
  6. Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, INVEST Investigators et al (2007) KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 17:719–729PubMedCentralPubMedGoogle Scholar
  7. Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J et al (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2(4):362–370PubMedCentralPubMedGoogle Scholar
  8. Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y (2012) Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. Clin Ther 34:811–823PubMedGoogle Scholar
  9. Berthold HK, Laaksonen R, Lehtimäki T, Gylling H, Krone W, Gouni-Berthold I (2008) SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp Clin Endocrinol Diabetes 116:262–267PubMedGoogle Scholar
  10. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE et al (2003) Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107:2416–2421PubMedGoogle Scholar
  11. Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P, Klungel OH (2009 May) Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 22(5):545–551PubMedGoogle Scholar
  12. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429–2436PubMedGoogle Scholar
  13. Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM (2012) LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res 53:556–560PubMedCentralPubMedGoogle Scholar
  14. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E (2001) The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 88:347–352PubMedGoogle Scholar
  15. Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM et al (2011) A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 29:509–519PubMedGoogle Scholar
  16. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106–4112PubMedCentralPubMedGoogle Scholar
  17. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, Anderson JL (2003) The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 146:1007–1014PubMedGoogle Scholar
  18. Cen HJ, Zeng WT, Leng XY, Huang M, Chen X (2010) CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 70:234–240PubMedCentralPubMedGoogle Scholar
  19. Chapman N, Chang CL, Caulfield M, Dahlöf B, Feder G, Sever PS, Poulter NR (2011) Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis 21:150–157PubMedGoogle Scholar
  20. Chasman DI, Posada D, Subrahmanyan L et al (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821–2827PubMedGoogle Scholar
  21. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM (2012) Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 5:257–264PubMedGoogle Scholar
  22. Chien KL, Wang KC, Chen YC et al (2010) Common sequence variants in pharmacodynamics and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics 11:309–317PubMedGoogle Scholar
  23. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB et al (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309–317PubMedGoogle Scholar
  24. Cuisset T, Morange PE, Alessi MC (2012) Recent advances in the pharmacogenetics of clopidogrel. Hum Genet 131:653–664PubMedGoogle Scholar
  25. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L et al (1997) Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353–1357PubMedGoogle Scholar
  26. D’Ambrosio RL, D’Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, Grandone E, Margaglione M (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89:1510–1516PubMedGoogle Scholar
  27. D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645–649PubMedGoogle Scholar
  28. Dörr M, Schmidt CO, Spielhagen T, Bornhorst A, Hentschel K (2010) β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant. Pharmacogenomics 11:1209–1221PubMedCentralPubMedGoogle Scholar
  29. El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM (2012) Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol 34:517–524PubMedGoogle Scholar
  30. Epstein RS, Moyer TP, Aubert RE, O’Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR (2010) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804–2812PubMedGoogle Scholar
  31. Fan YM, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Knuuti J, Lehtimäki T (2001) Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin Genet 60:319–321PubMedGoogle Scholar
  32. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005a) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78(5):551–558PubMedGoogle Scholar
  33. Fiegenbaum M, Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005b) Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J 5:359–364PubMedGoogle Scholar
  34. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, Skolnick M, Glorioso N (2004) Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 4:154–160PubMedGoogle Scholar
  35. Filigheddu F, Argiolas G, Degortes S, Zaninello R, Frau F, Pitzoi S, Bulla E, Bulla P, Troffa C, Glorioso N (2012) Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 11:319–325Google Scholar
  36. Fontana P, Hulot JS, De Moerloose P, Gaussem P (2007) Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 5:2153–2155PubMedGoogle Scholar
  37. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2004) Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J 4:17–23PubMedGoogle Scholar
  38. Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, Caslake MJ, Packard CJ, Gaffney D (2003) A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2420:1833–1842Google Scholar
  39. Fu R, Sun YM, Su Y, Wu Y, Luan Y (2008) Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol 35:982–983PubMedGoogle Scholar
  40. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326–331PubMedCentralPubMedGoogle Scholar
  41. Gandelman K, Fung GL, Messig M, Laskey R (2012) Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther 9:164–173Google Scholar
  42. Gaziano TA (2005) Cardiovascular disease in the developing world and its cost-effective management. Circulation 112:3547PubMedGoogle Scholar
  43. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M (2008) Cytochrome P450 2C19 and non-genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:1251–1259PubMedGoogle Scholar
  44. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P et al (1999) The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34:649–654PubMedGoogle Scholar
  45. Gonzalez-Conejero R, Rivera J, Corral J, Acuña C, Guerrero JA, Vicente V (2005) Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36:276–280PubMedGoogle Scholar
  46. Guzman EC, Hirata MH, Quintão EC, Hirata RD (2000) Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 38:731–736PubMedGoogle Scholar
  47. Hannuksela ML, Liinamaa MJ, Kesäniemi YA, Savolainen MJ (1994) Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 110:35–44PubMedGoogle Scholar
  48. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, PROGRESS Collaborative Group et al (2003) The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42:297–303PubMedGoogle Scholar
  49. Heidenreich PA, Trogdon JG, Khavjou OA et al (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933–944PubMedGoogle Scholar
  50. Heller DA, de Faire U, Pedersen NL et al (1993) Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 328:1150–1156PubMedGoogle Scholar
  51. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srino-uanprachanh SL, Farin FM, Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698PubMedGoogle Scholar
  52. Himbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M (2005) The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med 258:442–449PubMedGoogle Scholar
  53. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ (1995) Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 13:1602–1609PubMedGoogle Scholar
  54. Holloway JW, Yang IA, Ye S (2005) Variation in the toll-like receptor 4gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 15:15–21PubMedGoogle Scholar
  55. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244–2247PubMedGoogle Scholar
  56. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79:419–426PubMedGoogle Scholar
  57. Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, Huang J, Xiao HS, Zhan YY (2007) Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin Med J (Engl) 120:782–786Google Scholar
  58. Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, Wang GC, Wang HB, Zhuang MQ, Lu M (2012) CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther 37:719–723PubMedGoogle Scholar
  59. Johnson JA (2012) Advancing management of hypertension through pharmacogenomics. Ann Med 44(Suppl 1):S17–S22PubMedCentralPubMedGoogle Scholar
  60. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB (2012) Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 92:437–439PubMedCentralPubMedGoogle Scholar
  61. Kacevska M, Ivanov M, Ingelman-Sundberg M (2012) Epigenetic-dependent regulation of drug transport and metabolism: an update. Pharmacogenomics 13:1373–1385PubMedGoogle Scholar
  62. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2004) Polymorphisms in the multidrug resistance-1(MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93:1046–1050PubMedGoogle Scholar
  63. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ (2005) A promoter polymorphism in cholesterol 7alphahydroxylase interacts with apolipoprotein E genotype in the LDL lowering response to atorvastatin. Atherosclerosis 180:407–415PubMedGoogle Scholar
  64. Kardia SL, Sun YV, Hamon SC, Barkley RA, Boerwinkle E, Turner ST (2007) Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension. BMC Med Genet 8:61PubMedCentralPubMedGoogle Scholar
  65. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009) Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617–1624PubMedGoogle Scholar
  66. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R et al (2007) Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120:181–186PubMedGoogle Scholar
  67. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA (2003) Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C–>A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 12:111–123PubMedGoogle Scholar
  68. Klos KL, Kullo IJ (2007) Genetic determinants of HDL: monogenic disorders and contributions to variation. Curr Opin Cardiol 22:344–351PubMedGoogle Scholar
  69. Krauss RM, Mangravite LM, Smith JD et al (2008) Variation in the 3-hydroxyl-3-methylglutarylcoenzyme a reductase gene is associated with racial differences in low density lipoprotein cholesterol response to simvastatin treatment. Circulation 117:1537–1544PubMedGoogle Scholar
  70. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ (1998) The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 338:86–93PubMedGoogle Scholar
  71. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nyström F, Hägg A, Lind L (2001) Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 19(10):1783–1787PubMedGoogle Scholar
  72. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 20:657–663PubMedGoogle Scholar
  73. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L (2004) Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 17:8–13PubMedGoogle Scholar
  74. Lahoz C, Peña R, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A, RAP Study Group (2003) Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 168:289–295PubMedGoogle Scholar
  75. Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X (2005a) Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 54:741–747PubMedGoogle Scholar
  76. Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X, RAP Study Group (2005b) The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 182(1):129–134, Epub 26 Feb 2005PubMedGoogle Scholar
  77. Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G et al (2010) Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2(59):ra87Google Scholar
  78. Law M, Wald N, Morris J (2003) Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 7:1–94PubMedGoogle Scholar
  79. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS (2007) Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119:355–360PubMedGoogle Scholar
  80. Levitt MR, Osbun JW, Kim LJ (2012) The pharmacogenomics of clopidogrel. World Neurosurg 77:406–407PubMedGoogle Scholar
  81. Li Y, Zhou Y, Yang P, Niu JQ, Wu Y, Zhao DD, Wu SL (2011) Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. Clin Exp Hypertens 33:141–146PubMedGoogle Scholar
  82. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74:372–379PubMedGoogle Scholar
  83. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, Zhou G, Liu YZ, Li Q, Zhou HH (2006) Beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80:23–32PubMedGoogle Scholar
  84. Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I et al (2010) Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 8:1018–1026PubMedGoogle Scholar
  85. Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R (2009) A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension 54:796–801PubMedGoogle Scholar
  86. Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T (2012) Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol 96(6):719–728PubMedGoogle Scholar
  87. Maitland-van der Zee AH, Klungel OH, Leufkens HG, de Boer A, Stricker BH, Hofman A, Witteman JC, van Duijn CM, Kastelein JJ (2004) Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 175:377–379PubMedGoogle Scholar
  88. Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH (2007) Absence of an interaction between the angiotensin converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J 153:54–58PubMedCentralPubMedGoogle Scholar
  89. Malin R et al (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11(7):625–633PubMedGoogle Scholar
  90. Mangravite LM, Thorn CF, Krauss RM (2006) Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 6:360–374PubMedGoogle Scholar
  91. Mangravite LM, Medina MW, Cui J, Pressman S, Smith JD, Rieder MJ, Guo X, Nickerson DA, Rotter JI, Krauss RM (2010) Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol 30:1485–1492PubMedCentralPubMedGoogle Scholar
  92. Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, Zagato L, Delli Carpini S, Tantardini C, Brioni E, Bianchi G, Samani NJ (2008) Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension 52:366PubMedGoogle Scholar
  93. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O’Brien J, Crean P, Shields DC, Fitzgerald DJ (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3:2340–2345PubMedGoogle Scholar
  94. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM (2003) Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 35:89–95Google Scholar
  95. Marschang P, Sandhofer A, Ritsch A, Fiŝer I, Kvas E, Patsch JR (2006) Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med 260:151–159PubMedGoogle Scholar
  96. Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674PubMedGoogle Scholar
  97. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED et al (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328:914–921. Erratum in: N Engl J Med 330:1689, 1994Google Scholar
  98. Medina MW (2010) The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy. Discov Med 9:495–499PubMedGoogle Scholar
  99. Medina MW, Krauss RM (2009) The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med 19:173–177PubMedCentralPubMedGoogle Scholar
  100. Miniño AM, Murphy SL, Xu J, Kochanek KD (2011) Deaths: final data for 2008. National vital statistics reports, vol 59, no 10. National Center for Health Statistics, HyattsvilleGoogle Scholar
  101. Mohrschladt MF, van der Sman-de Beer F, Hofman MK, van der Krabben M, Westendorp RG, Smelt AH (2005) TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. Eur J Hum Genet 13:877–882PubMedGoogle Scholar
  102. Motovska Z, Kvasnicka J, Hajkova J, Kala P, Simek S et al (2010) Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: a genetic substudy of the PRAGUE-8 trial. Atherosclerosis 212:548–552PubMedGoogle Scholar
  103. Musunuru K, Roden DM, Boineau R, Bristow MR, McCaffrey TA et al (2012) Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart Assoc 1:e000554PubMedCentralPubMedGoogle Scholar
  104. Ned RM, Yesupriya A, Imperatore G, Smelser DT, Moonesinghe R, Chang MH, Dowling NF (2012) The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens 25:209–215PubMedGoogle Scholar
  105. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, Sikaris K, Sullivan D (1997) A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 129:231–239PubMedGoogle Scholar
  106. Niemi M (2007) Role of OATP transporters in disposition of drugs. Pharmacogenomics 8:787–802PubMedGoogle Scholar
  107. Niemi M (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130–133PubMedGoogle Scholar
  108. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype*17. Pharmacogenet Genomics 15:303–309PubMedGoogle Scholar
  109. Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–181PubMedGoogle Scholar
  110. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H et al (2010) Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 3:548–555PubMedCentralPubMedGoogle Scholar
  111. Nurden AT (1997) Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet 350:1189–1191PubMedGoogle Scholar
  112. Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ (1991) Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 230:397–405PubMedGoogle Scholar
  113. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, Schaefer EJ (1995) Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113:157–166PubMedGoogle Scholar
  114. Pamukcu B, Oflaz H, Nisanci Y (2005) The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 149:675–680PubMedGoogle Scholar
  115. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, Ordovas JM (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158:183–193PubMedGoogle Scholar
  116. Pena R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A, Rap Study Group (2002) Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J Intern Med 251:518–525PubMedGoogle Scholar
  117. Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, Van’t Slot R, de Boer A, Maitland-van der Zee AH (2010) Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 11:1065–1076PubMedGoogle Scholar
  118. Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, de Boer A, Maitland-van der Zee AH (2011) Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 217:458–464PubMedCentralPubMedGoogle Scholar
  119. Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR et al (2012) Effect of the Arg389Glyβ(1)-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol 39:779–785PubMedGoogle Scholar
  120. Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S (2012) Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis 22:831–835PubMedGoogle Scholar
  121. Rau T, Düngen HD, Edelmann F, Waagstein F, Lainščak M, Dimković S et al (2012) Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 92:21–28. Erratum in: Clin Pharmacol Ther 92:397, 2012Google Scholar
  122. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2:e312PubMedCentralPubMedGoogle Scholar
  123. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293PubMedGoogle Scholar
  124. Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD (2005) High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res 38:1389–1397PubMedGoogle Scholar
  125. Romaine SP, Bailey KM, Hall AS, Balmforth AJ (2010) The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10:1–11PubMedGoogle Scholar
  126. Salazar LA, Hirata MH, Quintão EC, Hirata RD (2000) Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 14:125–131PubMedGoogle Scholar
  127. Salek L, Lutucuta S, Ballantyne CM, Gotto AM Jr, Marian AJ (2002) Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl) 80:737–744Google Scholar
  128. Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104PubMedGoogle Scholar
  129. Sanllehy C, Casals E, Rodriguez-Villar C, Zambón D, Ojuel J, Ballesta AM, Ros E (1998) Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 47:560–565PubMedGoogle Scholar
  130. Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC (2011) SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 12:136PubMedCentralPubMedGoogle Scholar
  131. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC (2012) SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 68:273–279PubMedGoogle Scholar
  132. Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj M, de Boer A (2004) Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin Pharmacol Ther 75:394–402PubMedGoogle Scholar
  133. Schelleman H, Stricker BH, Verschuren WM, de Boer A, Kroon AA, de Leeuw PW, Kromhout D, Klungel OH (2006) Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J 6:22–26PubMedGoogle Scholar
  134. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D (2003) ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41:398–403PubMedGoogle Scholar
  135. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333PubMedGoogle Scholar
  136. Shiffman D, Trompet S, Louie JZ, Rowland CM, Catanese JJ et al (2012) Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS One 7:e38240PubMedCentralPubMedGoogle Scholar
  137. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635PubMedGoogle Scholar
  138. Sing K, Ballantyne CM, Ferlic L, Brugada R, Cushman I, Dunn JK, Herd JA, Pownall HJ, Gotto AM, Marian AJ (1999) Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 144:435–442PubMedGoogle Scholar
  139. Singer JB, Holdaas H, Jardine AG, Fellstrøm B, Os I et al (2007) Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 48:2072–2078PubMedGoogle Scholar
  140. Sofowora GG, Dishy V, Muszkat M, Xie HG et al (2003) A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73:366–371PubMedGoogle Scholar
  141. Sorkin SC, Forestiero FJ, Hirata MH, Guzmán EC, Cavalli SA, Bertolami MC, Salazar LA, Hirata RD (2005) APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 43:1339–1345PubMedGoogle Scholar
  142. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2012) SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med 50:441–448PubMedGoogle Scholar
  143. Srivastava K, Chandra S, Bhatia J, Narang R, Saluja D (2012) Association of angiotensinogen (M235T) gene polymorphism with blood pressure lowering response to angiotensin converting enzyme inhibitor (Enalapril). J Pharm Pharm Sci 15(3):399–406PubMedGoogle Scholar
  144. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis P, Kyriakidis M (2000) Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 14:427–432PubMedGoogle Scholar
  145. Superko HR, Momary KM, Li Y (2012) Statins personalized. Med Clin North Am 96:123–139PubMedGoogle Scholar
  146. Svensson-Färbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O (2011) A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J Hypertens 29:388–395PubMedGoogle Scholar
  147. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–380PubMedGoogle Scholar
  148. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese. Caucasians and African-Americans. Pharmacogenet Genomics 16:101–110PubMedGoogle Scholar
  149. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I (2006) Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 51:822–826PubMedGoogle Scholar
  150. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433PubMedCentralPubMedGoogle Scholar
  151. Takeuchi F, Yamamoto K, Katsuya T, Sugiyama T, Nabika T et al (2012) Reevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample size. Hypertens Res 35:825–831PubMedGoogle Scholar
  152. Thompson JF, Man M, Johnson KJ et al (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5:352–358PubMedGoogle Scholar
  153. Thompson JF, Hyde CL, Wood LS et al (2009) Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet 2:173–181PubMedGoogle Scholar
  154. Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM, Marian AJ (2001) A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154:633–640PubMedGoogle Scholar
  155. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2001) C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37:739–743PubMedGoogle Scholar
  156. Undas A, Sanak M, Musial J, Szczeklik A (1999) Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 353:982–983PubMedGoogle Scholar
  157. vanVenrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI Study Group (2003) Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type2 diabetes. Diabetes Care 26:1216–1223Google Scholar
  158. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2004) The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 92:61–66PubMedGoogle Scholar
  159. Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR et al (2008) Pharmacogenetic predictors of statin mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 1:100–106PubMedCentralPubMedGoogle Scholar
  160. Vrablík M, Hubáček JA, Dlouhá D, Lánská V, Rynekrová J, Zlatohlávek L, Prusíková M, Ceška R, Adámková V (2012) Impact of variants within seven candidate genes on statin treatment efficacy. Physiol Res 61(6):609–617PubMedGoogle Scholar
  161. Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99–111PubMedGoogle Scholar
  162. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784–792PubMedCentralPubMedGoogle Scholar
  163. Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K et al (2003) Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J 3:284–296PubMedGoogle Scholar
  164. Ye P, Shang Y, Ding X (2003) The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin Med Sci J 18:9–13PubMedGoogle Scholar
  165. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745–1751PubMedGoogle Scholar
  166. Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK (2012) Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS One 7:e34217PubMedCentralPubMedGoogle Scholar
  167. Zhou Y, Wu SL, Liu JQ, Liang WN, Liu GF (2007) Possible association of ACE gene I/D polymorphism with blood pressure–lowering response to hydrochlorothiazide. Biomed Environ Sci 20:351–356PubMedGoogle Scholar
  168. Zuern CS, Schwab M, Gawaz M, Geisler T (2010) Platelet pharmacogenomics. J Thromb Haemost 8:1147–1158PubMedGoogle Scholar

Copyright information

© Springer India 2013

Authors and Affiliations

  1. 1.Laboratory of Molecular Cancer PathologyNational Institutes of HealthBethesdaUSA

Personalised recommendations